Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), will present at the 43rd Annual J.P. Morgan Healthcare ...
Graft-Versus-Host disease market Insights. DelveInsight's Graft-Versus-Host Disease Market report offers an in-depth understanding of the epidemiology and ...
IST, the barometer index, the S&P BSE Sensex, gained 308.37 points or 0.40% to 78,273.36. The Nifty 50 index added 124.10 points or 0.53% to 23,744.20.
Stock Market LIVE Updates | Indian stocks experienced heavy selling due to worries about the HMP Virus outbreak and a ...
The Indian stock market snapped its two-day losing streak on Tuesday, January 7, with benchmarks Sensex and Nifty 50 posting ...
The domestic equity indices staged a rebound on Tuesday, ending with modest gains after two consecutive days of declines. The Nifty 50 index closed above the 23,700 mark, driven by gains in energy and ...
Dr. Agarwal Health Care, backed by Temasek and TPG, received SEBI's approval for a Rs 300 crore IPO. The offering includes a fresh issue and sale by promoters. Proceeds will address debt repayment, ...
Biocon shares rose 9% to ₹389, driven by positive developments including Japanese approval for its biosimilar Ustekinumab.
International brokerage Jefferies has upgraded its rating on drugmaker Biocon to 'hold' citing positive newsflow around the regulatory approval of its Bengaluru manufacturing unit. Building on the ...
This detailed review of HSBC Midcap Fund evaluates its recent performance, comparing it to the Nifty index, and analyzes key ...
Shares of Biocon surged 7.79 per cent to ₹386.55 on the BSE at 12:08 pm after the company announced that its biosimilar Ustekinumab had received regulatory approval in Japan. According to its ...